Telomerase and cancer therapeutics

Nature Reviews Cancer

Volumn 8, Issue 3, 2008, Pages 167-179

  Harley, Calvin B ^a  

^a GERON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; TELOMERASE; TELOMERASE INHIBITOR;

BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CANCER TISSUE; CELL KINETICS; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG INHIBITION; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LIVER CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; KINETICS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; NEOPLASMS; OLIGOPEPTIDES; TELOMERASE;

EID: 39749163359     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2275     Document Type: Review

References (143)

1. Hanahan, J. D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. Harley, C. B. et al. Telomerase, cell immortality, and cancer. Cold Spring Harbor Symp. Quant. Biol. 59, 307-315 (1994).
3. Hahn, W. C. et al. Inhibition of telomerase limits the growth of human cancer cells. Nature Med. 5, 1164-1170 (1999).
4. Kelland, L. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin. Cancer Res. 13, 4960-4963 (2007).
5. Greider, C. W. & Blackburn, E. H. Identification of a specific telomere terminal transferase enzyme with two kinds of primer specificity. Cell 51, 405-413 (1985). The discovery of the biochemical activity of telomerase is reported in a protozoan, enabling future work on the role of telomeres and telomerase in human ageing and cancer.
6. Greider, C. W. & Blackburn, E. H. A telomeric sequence in the RNA of tetrahymena telomerase required for telomere repeat synthesis. Nature 337, 331-337 (1989).
7. Liu, D., O'Connor, M. S., Qin, J. & Songyang, Z. Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins. J. Biol. Chem. 279, 51338-51342 (2004).
8. de Lange, T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19, 2100-2110 (2005). In this and the preceding reference, the collection of telomere-binding proteins is put into an emerging structure for the chromosome tip, the 'telosome' or 'shelterin', and potential interactions with telomerase are summarized.
9. Harley, C. B., Futcher, A. B. & Greider, C. W. Telomeres shorten during ageing of human fibroblasts. Nature 345, 458-460 (1990). The association between telomere loss and replicative ageing in normal human somatic cells is first reported.
10. Hastie, N. D. et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346, 866-868 (1990). The first broad survey of telomere lengths in premalignant and malignant tumour samples finds short telomeres in malignant cancer tissue.
11. Wellinger, R. J., Ethier, K., Labrecque, P. & Zakian, V. A. Evidence for a new step in telomere maintenance. Cell 16, 3094-3105 (1996).
12. Jacob, N. K., Kirk, K. E. & Price, C. M. Generation of telomeric G strand overhangs involves both G and C strand cleavage. Mol. Cell 11, 1021-1032 (2003).
13. Goldkorn, A. & Blackburn, E. H. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res. 66, 5763-5771 (2006).
14. Wright, W. E., Piatyszek, M. A., Rainey, W. E., Byrd, W. & Shay, J. W. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 18, 173-179 (1996).
15. Ulaner, G. A., Hu, J.-F., Vu, T. H., Giudice, L. C. & Hoffman, A. R. Telomerase activity in human development is regulated both by hTERT transcription and by alternate splicing of hTERT transcripts. Cancer Res. 58, 4168-4172 (1998).
16. Kakuo, S., Asaoka, K. & Ide, T. Human is a unique species among primates in terms of telomere length. Biochem. Biophys. Res. Comm. 263, 308-314 (1999).
17. Steinert, S., White, D., Zou, Y., Shay, J. W. & Wright, W. E. Telomere biology and cellular aging in non-human primate cells. Exp. Cell Res. 272, 146-152 (2002).
18. Okuda, K. et al. Telomere length in the newborn. Pediatr. Res. 52, 377-381 (2002).
19. Bodnar, A., Kim, N. W., Effros, R. B. & Chiu, C.-P. Mechanism of telomerase induction during T cell activation. Exp. Cell Res. 228, 58-64 (1996).
20. Broccoli, D., Young, J. W. & de Lange, T. Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl Acad. Sci. 92, 9082-9086 (1995).
21. Chiu, C. P. et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 14, 239-248 (1996).
22. Harley, C. B. Telomere loss: mitotic clock or genetic time bomb? Mut. Res. 256, 271-282 (1991).
23. Counter, C. M. et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11, 1921-1929 (1992). Critically shortened telomeres in a model of cell transformation and immortalization are shown to be linked to genetic rearrangements that are stabilized when telomerase is activated.
24. Δ2/3 cancer-prone mouse. Cell 97, 515-525 (1999).
25. Hanahan, D. Benefits of bad telomeres. Nature 406, 573-574 (2000).
26. Harley, C. B. Telomerase is not an oncogene. Oncogene 21, 494-502 (2002).
27. Khoo, C. M., Carrasco, D. R., Bosenberg, M. W., Paik, J.-H. & DePinho, R. A. Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proc. Natl Acad. Sci. USA 104, 3931-3936 (2007).
28. Cawthon, R. M., Smith, K. R., O'Brien, E., Sivatchenko, A. & Kerber, R. A. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361, 359-395 (2003). A simple and rapid telomere length assay developed by the lead author is used in a human epidemiology study, demonstrating increased mortality risk of cancer in individuals with short telomeres.
29. Epel, E. S. et al. Accelerated telomere shortening in response to life stress. Proc. Natl Acad. Sci. 101, 17312-17315 (2004).
30. Benetos, A. et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 43, 182-185 (2004).
31. Vulliamy, T. et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nature Genet. 36, 447-449 (2004).
32. Walne, A., Marrone, A. & Dokal, I. Dyskeratosis congenita: a disorder of defective telomere maintenance? Int. J. Hematol. 82, 184-189 (2005).
33. Demissle, S. et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell 5, 325-330 (2006).
34. Fitzpatrick, A. L. et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am. J. Epidemiol. 165, 14-21 (2007).
35. Brouilette, S. W. et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 369, 107-114 (2007).
36. Armanios, M. Y. et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356, 1370-1372 (2007).
37. Kim, N. W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2014 (1994). A highly sensitive PCR assay for telomerase activity (TRAP) is reported, enabling detection of telomerase in a broad range of tumour cell lines and in certain normal cells.
38. Shay, J. W. & Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787-791 (1997).
39. Keith, W. N., Bilsland, A., Hardie, M. & Evans, T. R. Drug Insight: cancer cell immortality - telomerase as a target for novel cancer gene therapies. Nat. Clin. Pract. Oncol. 1, 88-96 (2004).
40. Zimmermann, S. & Martens, U. M. Telomeres and telomerase as targets for cancer therapy Cell. Mol. Life Sci. 64 906-921 (2007).
41. Phatak, P. & Burger, A. M. Telomerase and its potential for therapeutic intervention. Br. J. Pharmacol. (2007).
42. Finkel, T., S. M. & Blasco, M. A. The common biology of cancer and ageing. Nature 448, 767-774 (2007).
43. Blasco, M. A. Telomere length, stem cells and aging. Nature Chem. Biol. 3, 640-649 (2007).
44. Greider, C. W. Telomeres, telomerase and senescence. BioEssays 12, 363-368 (1990).
45. Feng, J. et al. The RNA component of human telomerase. Science 269, 1236-1241 (1995). The RNA component of human telomerase is cloned and characterized, enabling specific modulation of telomerase activity and facilitating the discovery of telomerase inhibitors targeting the RNA template region of telomerase.
46. Nakamura, T. M. et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 277, 955-959 (1997). The catalytic protein component of human telomerase (TERT) is cloned, enabling further experimental manipulation of telomerase in normal and tumour tissues, and the development of the first telomerase-based drugs (TERT vaccines) to enter clinical trials.
47. Meyerson, M. et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785-795 (1997).
48. Harrington, L. et al. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. 11, 3109-3115 (1997).
49. Weinrich, S. L. et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nature Genet. 17, 498-502 (1997).
50. Kilian, A. et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6, 2011-2019 (1997).
51. Nakayama, J.-I. et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nature Genet. 18, 65-68 (1998).
52. Cortez-Gonzalez, X. & Zanetti, M. Telomerase immunity from bench to bedside: round one. J. Transl. Med. 5, 12 (2007).
53. Fakhoury, J., Nimmo, G. A. & Autexier, C. Harnessing telomerase in cancer therapeutics. Anticancer Agents Med. Chem. 7, 475-483 (2007).
54. Hiyama, E. & Hiyama, K. Telomerase as tumor marker. Cancer Lett. 194, 221-233 (2003).
55. Armanios, M. & Greider, C. W. Telomerase and cancer stem cells. Cold Spring Harb. Symp. Quant. Biol. 70, 205-208 (2005).
56. Ho, M. M., Nq, A. V., Lam, S. & Hung., J. Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827-4833 (2007).
57. Phatak, P. et al. Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br. J. Cancer 96, 1223-1233 (2007).
58. Camp, E. R. et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin. Cancer Res. 11, 397-405 (2005).
59. Bilsland, A. E. et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 22, 370-380 (2003). In vivo proof of concept using a prodrug suicide gene approach driven by either the hTR or the TERT promoter in a non-oncolytic adenoviral vector.
60. Zhang, Q. et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin. Cancer Res. 12, 6523-6531 (2006).
61. Irving, J. et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther. 11, 174-185 (2004). In vivo proof of concept and demonstration of safety for a conditional replicative oncolytic virus driven by the TERT promoter.
62. Li, S., Crothers, J., Haqq, C. M. & Blackburn, E. H. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J. Biol. Chem. 280, 23709-23717 (2005).
63. Xu, L. & Blackburn, E. H. Human cancer cells harbor T-stumps, a distinct class of extremely short telomeres. Mol. Cell. 28, 315-327 (2007).
64. Haider, S. M., Parkinson, G. N. & Neidle, S. Structure of a G-quadruplex-ligand complex. J. Mol. Biol. 326, 117-125 (2003).
65. Patel, D., Phan, A. & Kuryavyi, V. Human telomere, oncogenic promoter and 5′-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. Nucl. Acids Res. 35, 7429-7455 (2007).
66. Gowan, S. et al. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol. Pharmacol. 61, 1154-1162 (2002).
67. Gunaratnam, M. et al. Mechanism of acridine-based telomerase inhibition and telomere shortening. Biochem. Pharmacol. 74, 679-689 (2007).
68. Salvati, E. et al. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J. Clin. Invest. 117, 3236-3247 (2007). In vivo proof of concept for a late preclinical drug candidate targeting the telomere.
69. Oganesian, L. & Bryan, T. Physiological relevance of telomeric G-quadruplex formation: a potential drug target. Bioessays 29, 155-165 (2007).
70. Pascolo, E. et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J. Biol. Chem. 277, 15566-15572 (2002).
71. Ward, R. J. & Autexier, C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol. Pharmacol. 68, 779-786 (2005).
72. Barma, D. K., Elayadi, A., Falck, J. R. & Corey, D. R. Inhibition of telomerase by BIBR 1532 and related analogues. Bioorg. Med. Chem. Lett. 13, 1333-1336 (2003).
73. Piotrowska, K. et al. Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors. Lab. Invest. 85, 1565-1569 (2005). Care must be taken in using the standard PCR-based TRAP assay for evaluation of telomerase inhibitors.
74. Zhou, S. et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Med. 7, 1028-1034 (2001).
75. Asai, A. et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 63, 3931-3939 (2003).
76. Herbert, B. et al. Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24, 5262-5268 (2005). GRN163L, a telomerase inhibitor now in clinical trials, is demonstrated to have significantly enhanced cellular activity compared with its non-lipidated parent compound, GRN163.
77. Dikmen, Z. G. et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 65, 1-8 (2005).
78. Jackson, D. A. et al. Antiadhesive effects of GRN163L - an oligonucleotide N3′→P5′ thio-phosphoramidate targeting telomerase. Cancer Res. 67, 1121-1129 (2007).
79. Gellert, G. C., Dikmen, Z. G., Wright, W. E., Gryaznov, S. & Shay, J. W. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treat. 1-9 (2005).
80. Hochreiter, A. E. et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin. Cancer Res. 12, 3184-3192 (2006).
81. Gomez-Millan, J., Goldblatt, E. M., Gryaznov, S. M., Mendonca, M. S. & Herbert, B. S. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 67, 897-905 (2007). A representative report illustrating the telomere length-dependent activity of GRN163L in certain tumours, and synergy of telomerase inhibition and radiation in models of breast cancer.
82. Djojosubroto, M. W. et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 42, 1-12 (2005).
83. Ozawa, T. et al. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro Oncol. 6, 218-226 (2004).
84. Dikmen, Z. G., Wright, W. E., Shay, J. W. & Gryaznov, S. M. Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells. J. Cell Biochem. (2007).
85. Akiyama, M. et al. Effects of oligonucleotide N3′→ P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 63, 6187-6194 (2003).
86. Wang, E. S. et al. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103, 258-266 (2004).
87. Nair, N. K. et al. Induction of cytotoxic T cells responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nature Med. 6, 1011-1013 (2000).
88. Vonderheide, R. et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 61, 8366-8370 (2001).
89. Cohen, S. B. et al. Protein composition of catalytically active human telomerase from immortal cells. Science 315, 1850-1853 (2007). The first report of a substantially pure form of human telomerase and the essential protein components associated with telomerase activity in a cell-free system.
90. Gannage, M. et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J. Immunol. 174, 8210-8218 (2005).
91. + T lymphocytes in cancer patients. Blood 107, 1505-1512 (2005).
92. Nava-Parada, P. & Emens, L. A. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. Curr. Opin. Mol. Ther. 9, 490-497 (2007). The immulogical and apparent clinical responses with GV1001, a telomerase peptide vaccine now in phase II and III studies, are reported.
93. Brunsvig, P. F. et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 55, 1553-1564 (2006).
94. + T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res. 62, 5041-5048 (2002).
95. Dikmen, Z. et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 7866-7873 (2005).
96. + T lymphocytes. Clin. Cancer Res. 10, 828-839 (2004).
97. + T cell responses in patients with metastatic prostate cancer. J. Immunol. 174, 3798-3807 (2005). Strong immunological responses and signs of apparent clinical activity associated with immune responses are reported in prostate cancer patients given autologous TERT mRNA-transfected dendritic cell vaccines.
98. 572Y in patients with advanced malignancies. Oncology 70, 306-314 (2006).
99. Parkhurst, M. R. et al. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res. 10, 4688-4698 (2004).
100. Domchek, S. M. et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res. 67, 10546-10555 (2007). Induction of TERT-specific tumour-infiltrating cytotoxic T cells is associated with apparent signs of clinical activity with a TERT peptide vaccine, and patients with induced immune responses had longer median survival than those without induced immune responses.
101. Ramirez, R. D., Wright, W. E., Shay, J. W. & Taylor, R. S. Implications of telomerase activity in human hair follicles. J. Invest. Dermatol. 108, 113-117 (1997).
102. Danet-Desnoyers, G. A., Luongo, J. L., Bonnet, D. A., Domchek, S. M. & Vonderheide, R. H. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp. Hematol. 33, 1275-1280 (2005).
103. H gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br. J. Cancer 88, 593-598 (2003).
104. Damle, R. N. et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 103, 375-382 (2004).
105. Counter, C. M., Hirte, H. W., Bacchetti, S. & Harley, C. B. Telomerase activity in human ovarian carcinoma. Proc. Natl Acad. Sci. USA 91, 2900-2904 (1994). The first demonstration of specific telomerase expression in human tumour biopsy samples.
106. Saretzki, G., Ludwig, A., von Zglinicki, T. & Runnebaum, I. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther. 8, 827-834 (2001).
107. Jiang, F., Bao, J., Li, P., Nicosia, S. V. & Bai, W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation. J. Biol. Chem. 279, 53213-53221 (2004).
108. Roth, A. et al. Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. Leukemia 21, 2456-2462 (2007).
109. Wong, K.-K. et al. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nature Genet. 26, 85-88 (2000).
110. Tacken, P. J., de Vries, J. M., Torensma, R. & Figdor, C. G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature Rev. Immunol. 7, 790-802 (2007).
111. Effros, R. B. Telomerase induction in T cells: A cure for aging and disease? Exp. Gerontol. 42, 416-420 (2007).
112. Goronzy, J. J. et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J. Virol. 75, 12182-12187 (2001).
113. Ostergaard, M., Olesen, L. H., Hasle, H. & Hokland, K. E. WT1 gene expression: An excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukemia patients - results from a single centre study. Br. J. Haematol. 125, 590-600 (2004).
114. Roth, A. et al. Telomerase levels control the lifespan of human T lymphocytes. Blood 102, 849-857 (2003).
115. Vaziri, H. et al. Evidence for a mitotic clock in human hematopoietic stem cells: Loss of telomeric DNA with age. Proc. Natl Acad. Sci. USA 91, 9857-9860 (1994).
116. Engelhardt, M. et al. Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia 12, 13-24 (1998).
117. Ricca, I. et al. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF. Leukemia 19, 644-651 (2005).
118. Thornley, I. et al. Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. Blood 99, 2387-2396 (2002).
119. Franco, S. et al. Telomere dynamics in childhood leukemia and solid tumors: a follow-up study. Leukemia 17, 401-410 (2003).
120. Harley, C. B. Telomerase therapeutics for degenerative diseases. Curr. Mol. Med. 5, 205-211 (2005).
121. Zhong, Z. H. et al. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J. Biol. Chem. 282, 29314-29322 (2007).
122. Chang, S., Khoo, C. M., Naylor, M. L., Maser, R. S. & DePinho, R. A. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev. 17, 88-100 (2003).
123. Unryn, B., Cook, L. & Riabowol, K. Paternal age is positively linked to telomere length of children. Aging Cell 4, 97-101 (2005).
124. Njajou, O. T. et al. Telomere length is paternally inherited and is associated with parental lifespan. Proc. Natl Acad. Sci. USA 104, 12135-12139 (2007).
125. Ulaner, G. A. & Giudice, L. C. Developmental regulation of telomerase activity in human fetal tissues during gestation. Mol. Hum. Reprod. 3, 769-773 (1997).
126. Xu, J. & Yang, X. Telomerase activity in bovine embryos during early development. Biol. Reprod. 63, 1124-1128 (2000).
127. Schaetzlein, S. et al. Telomere length is reset during early mammalian embryogenesis. Proc. Natl Acad. Sci. USA 101, 8034-8038 (2004).
128. d'Adda di Fagagna, D. et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198 (2003).
129. Karlseder, J., Smogorzewska, A. & de Lange, T. Senescence induced by altered telomere state, not telomere loss. Science 295, 2446-2449 (2002).
130. Levy, M. Z., Allsopp, R. C., Futcher, A. B., Greider, C. W. & Harley, C. B. Telomere end-replication problem and cell aging. J. Mol. Biol. 225, 951-960 (1992).
131. Baerlocher, G. M., Vulto, I., de Jong, G. & Lansdorp, P. M. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nature Protoc. 1, 2365-2376 (2006).
132. van Steensel, B. & de Lange, T. Control of telomere length by the human telomeric protein TRF1. Nature 385, 740-743 (1997).
133. Teixeira, M. T., Arneric, M., Sperisen, P. & Lingner, J. Telomere length homeostasis is achieved via a switch between telomerase- extendible and -nonextendible states. Cell 117, 323-335 (2004).
134. Ouellette, M. et al. Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase. J. Biol. Chem. 275, 10072-10076 (2000).
135. Liu, Y., Kha, H., Ungrin, M., Robinson, M. O. & Harrington, L. Preferential maintenance of critically short telomeres in mammalian cells heterozygous for mTert. Proc. Natl Acad. Sci. USA 99, 3597-3602 (2002).
136. Hug, N. & Lingner, J. Telomere length homeostasis. Chromosoma 115, 413-425 (2006).
137. Wallweber, G., Gryaznov, S., Pongracz, K. & Pruzan, R. Interaction of human telomerase with its primer substrate. Biochemistry 42, 589-600 (2003). Analysis of human telomerase primer binding and dissociation kinetics enabled characterization of the mechanism of action of template antagonist telomerase inhibitor GRN163L.
138. Hemann, M., Strong, M., Hao, L. & Greider, C. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107, 67-77 (2001).
139. Baird, D. M. Telomere dynamics in human cells. Biochimie 90, 116-121 (2008).
140. Mitchell, J. R., Cheng, J. & Collins, K. A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3′ end. Mol. Cell. Biol. 19, 567-576 (1999).
141. Bernhardt, S. L. et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br. J. Cancer 95, 1474-1482 (2006).
142. Bolonaki, I. et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J. Clin. Oncol. 25, 2727-2734 (2007).
143. Millard, F. E., Gerloni, M., Derrah, D., Farness, P. & Zanetti, M. Phase I study of transgenic B lymphocyte immunization (TLI) against telomerase in androgen-independent prostate cancer (PC). J. Clin. Oncol. 22, 2459 (2004).